Skip to Main Content

Paper Details

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
AIDS
6
2022
B/, B/F, CD4 +, HIV, HIV disease, HIV-1 RNA, M184V, Participant, TAF, bictegravir, emtricitabine, participants, people, proviral DNA, proviral DNA genotype, tenofovir alafenamide
Author NameAffiliation
Paul E SaxBrigham and Women's Hospital and Harvard Medical School
Eric S DaarThe Lundquist Institute at Harbor-university of california los angeles Medical Center
Joel E GallantGilead Sciences Inc.
  • 1 - 3

Datasets

Release 1.2